Search - tctmd.com

Displaying 61 - 80 of 488

Sort: Relevancy | Date

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

November 13, 2024

October 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

October 25, 2024

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

News Daily News

Study Validates Accuracy of PREVENT for CVD Mortality Risk Prediction

October 15, 2024

AHA Statement Outlines Cardiac Contributions to Brain Health

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

October 11, 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

October 01, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

News Daily News

CVD Risk Twofold Higher in Patients With Cancer: ASPREE

Michael O'Riordan

September 27, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

September 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

September 01, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

August 21, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

CMS Announces Negotiated Medicare Prices for First 10 Drugs

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.